Literature DB >> 3158274

Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.

B Joos, B Ledergerber, M Flepp, J D Bettex, R Lüthy, W Siegenthaler.   

Abstract

Ciprofloxacin was given orally to 10 healthy volunteers for seven consecutive doses of 250 mg every 12 h. Serum and urine samples were collected at distinct times between 0 and 96 h and analyzed both by high-pressure liquid chromatography and by a microbiological assay. The detection limits were 0.006 and 0.03 microgram/ml, respectively. For each method, imprecision coefficients of variation were less than 6.1% at various concentrations in serum and urine. The means +/- standard deviations of the absolute values of the relative differences between the two methods were 9.3 +/- 6.8% (n = 225) for serum samples and 58.5 +/- 50.4% (n = 70) for urine samples. Comparison of the concentrations in serum measured with high-pressure liquid chromatography and bioassay by regression analysis yielded a slope which was not significantly different from 1.0 (99.9% confidence limits: 0.984 less than slope less than 1.035). In urine, however, the bioassay results were markedly higher than the high-pressure liquid chromatography values (1.327 less than slope less than 1.698), which indicates the presence of antimicrobially active metabolites. The cumulative 12-h urinary recovery after the first and seventh doses averaged 30.2 +/- 8.5 and 26.4 +/- 4.6%, respectively, by high-pressure liquid chromatography, whereas with bioassay 38.2 +/- 5.9 and 45.5 +/- 5.9% activity was recovered. Protein binding appeared to be neither concentration nor pH dependent and averaged 21.9 +/- 4.1%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158274      PMCID: PMC176276          DOI: 10.1128/AAC.27.3.353

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  [On-line measurement of antibiotic concentrations (author's transl)].

Authors:  J Grimm; H Bhend; R Lüthy; W Siegenthaler
Journal:  Microsc Acta Suppl       Date:  1979

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.

Authors:  J Shimada; T Yamaji; Y Ueda; H Uchida; H Kusajima; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

5.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin.

Authors:  B Ledergerber; J D Bettex; B Joos; M Flepp; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

10.  Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.

Authors:  V K Boppana; B N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

View more
  36 in total

1.  Effect of staggered dose of calcium on the bioavailability of ciprofloxacin.

Authors:  B M Lomaestro; G R Bailie
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Spectrofluorimetric quantification of antibiotic drug concentration in bacterial cells for the characterization of translocation across bacterial membranes.

Authors:  Julia Vergalli; Estelle Dumont; Jelena Pajović; Bertrand Cinquin; Laure Maigre; Muriel Masi; Matthieu Réfrégiers; Jean-Marie Pagés
Journal:  Nat Protoc       Date:  2018-05-17       Impact factor: 13.491

Review 3.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.

Authors:  M A Gonzalez; A H Moranchel; S Duran; A Pichardo; J L Magana; B Painter; A Forrest; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

5.  Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.

Authors:  K Borner; G Höffken; H Lode; P Koeppe; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reinitz
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

6.  Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.

Authors:  Adam L Vanwert; Chutima Srimaroeng; Douglas H Sweet
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

Review 7.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

8.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration.

Authors:  R Raina; S Prawez; D J Dimitrova; N K Pankaj; P K Verma
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

10.  Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.

Authors:  Andres F Zuluaga; Maria Agudelo; Carlos A Rodriguez; Omar Vesga
Journal:  BMC Clin Pharmacol       Date:  2009-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.